68 listed sites: Canada (8); China (5); France (6); Italy (5); Japan (5); Mexico (4); Poland (8); Spain (6); United States (21) - 04 Sep `26Zasocitinib tablets for nonsegmental vitiligo

Zasocitinib tablets for nonsegmental vitiligo

Official title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo

Status: Recruiting now

Description:

Takeda plans to enroll about 200 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 18 to 75 may qualify. The study is recruiting at 70 listed sites across 9 countries.

Start date: November 03, 2025

Completion date: November 09, 2027

Organizer: Takeda

Contact: Takeda Contact

Tel.: +1-877-825-3327

Email: medinfoUS@takeda.com

Link: https://clinicaltrials.gov/study/NCT07108283

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Zasocitinib tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Will it spread?

    Vitiligo is famously unpredictable, but it doesn't move at random. By looking at thousands of cases, researchers have identified specific patterns of how the condition behaves. ...

  • How Vitiligo Changes with Age?

    Vitiligo, a condition characterized by the loss of skin pigmentation, can affect individuals at any stage of life. While it often appears before the age of 20, its progression a...

  • Is vitiligo contagious?

    Vitiligo is not contagious. This means it cannot be spread from person to person through physical contact, sharing personal items, or any other means of transmission. Vitiligo i...